Elevated plasma levels of MMP-12 are associated with atherosclerotic burden and symptomatic cardiovascular disease in subjects with type 2 diabetes

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 35, Issue 7, 2015, Pages 1723-1731

  Goncalves, Isabel ^a   Bengtsson, Eva ^a   Colhoun, Helen M ^b   Shore, Angela C ^c   Palombo, Carlo ^d   Natali, Andrea ^d   Edsfeldt, Andreas ^a   Dunér, Pontus ^a   Fredrikson, Gunilla Nordin ^a   Björkbacka, Harry ^a   Östling, Gerd ^a   Aizawa, Kunihiko ^c   Casanova, Francesco ^c   Persson, Margaretha ^a   Gooding, Kim ^c   Strain, David ^c   Khan, Faisel ^b   Looker, Helen C ^b   Adams, Fiona ^b   Belch, Jill ^b   Pinnoli, Silvia ^d   Venturi, Elena ^d   Kozakova, Michaela ^d   Gan, Li Ming ^e   Schnecke, Volker ^e   Nilsson, Jan ^a   more..

^a LUND UNIVERSITY   (Sweden)

^b UNIVERSITY OF DUNDEE   (United Kingdom)

^c UNIVERSITY OF EXETER MEDICAL SCHOOL   (United Kingdom)

^d UNIVERSITY OF PISA   (Italy)

^e ASTRAZENECA R AND D   (Sweden)

Author keywords

atherosclerosis; cardiovascular disease; diabetes; matrix metalloproteinase

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; COLLAGEN; ELASTIN; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 6; INTERSTITIAL COLLAGENASE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MACROPHAGE ELASTASE; MATRILYSIN; METFORMIN; STROMELYSIN; STROMELYSIN 2; TRIACYLGLYCEROL;

ACUTE HEART INFARCTION; AGED; ANKLE BRACHIAL INDEX; ARTERIAL STIFFNESS; ARTERIAL WALL THICKNESS; ARTICLE; ATHEROSCLEROSIS; BODY MASS; CARDIOVASCULAR DISEASE; CAROTID ENDARTERECTOMY; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; COMMON CAROTID ARTERY; CONTROLLED STUDY; ENZYME LOCALIZATION; FEMALE; FOLLOW UP; FRAMINGHAM RISK SCORE; GLOMERULUS FILTRATION RATE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HUMAN TISSUE; HYPEREMIA; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PULSE WAVE; SMOKING; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; AGE; ATHEROSCLEROTIC PLAQUE; BLOOD; CORONARY ARTERY DISEASE; DIABETIC ANGIOPATHY; DIABETIC NEPHROPATHY; ENZYMOLOGY; PATHOPHYSIOLOGY;

AGE FACTORS; CORONARY ARTERY DISEASE; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DIABETIC NEPHROPATHIES; HUMANS; MATRIX METALLOPROTEINASE 1; MATRIX METALLOPROTEINASE 10; MATRIX METALLOPROTEINASE 12; MATRIX METALLOPROTEINASE 3; MATRIX METALLOPROTEINASE 7; PLAQUE, ATHEROSCLEROTIC; VASCULAR STIFFNESS;

EID: 84933048933     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.115.305631     Document Type: Article

References (32)

1. Beckman JA, Creager MA, Libby P., Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA 2002 287 2570 2581
2. Sattar N., Revisiting the links between glycaemia, diabetes and cardiovascular disease. Diabetologia 2013 56 686 695. doi: 10.1007/s00125-012-2817-5
3. Gregg EW, Cheng YJ, Saydah S, Cowie C, Garfield S, Geiss L, Barker L., Trends in death rates among U.S. adults with and without diabetes between 1997 and 2006: findings from the National Health Interview Survey. Diabetes Care 2012 35 1252 1257. doi: 10.2337/dc11-1162
4. Andersen P, Nilsen DW, Lyberg Beckmann S, Holme I, Hjermann I., Increased fibrinolytic potential after diet intervention in healthy coronary high-risk individuals. Acta Med Scand 1988 223 499 506
5. Brownlee M., The pathobiology of diabetic complications: a unifying mechanism. Diabetes 2005 54 1615 1625
6. Nilsson J, Bengtsson E, Fredrikson GN, Björkbacka H., Inflammation and immunity in diabetic vascular complications. Curr Opin Lipidol 2008 19 519 524. doi: 10.1097/MOL.0b013e32830f47cd
7. Edsfeldt A, Gonçalves I, Grufman H, Nitulescu M, Dunér P, Bengtsson E, Mollet IG, Persson A, Nilsson M, Orho-Melander M, Melander O, Björkbacka H, Nilsson J., Impaired fibrous repair: a possible contributor to atherosclerotic plaque vulnerability in patients with type II diabetes. Arterioscler Thromb Vasc Biol 2014 34 2143 2150. doi: 10.1161/ATVBAHA.114.303414
8. Hansson GK., Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005 352 1685 1695. doi: 10.1056/NEJMra043430
9. Libby P, Ridker PM, Maseri A., Inflammation and atherosclerosis. Circulation 2002 105 1135 1143
10. Bäck M, Ketelhuth DF, Agewall S., Matrix metalloproteinases in atherothrombosis. Prog Cardiovasc Dis 2010 52 410 428. doi: 10.1016/j.pcad.2009.12.002
11. Newby AC., Matrix metalloproteinase inhibition therapy for vascular diseases. Vascul Pharmacol 2012 56 232 244. doi: 10.1016/j.vph.2012.01.007
12. Shore AC, Colhoun HM, Natali A, Measures of atherosclerotic burden are associated with clinically manifest cardiovascular disease in type 2 diabetes: a European cross-sectional study. J Intern Med 2015. in press. doi: >10.1111/joim.12359
13. Rattik S, Wigren M, Björkbacka H, Fredrikson GN, Hedblad B, Siegbahn A, Bengtsson E, Schiopu A, Edsfeldt A, Dunér P, Grufman H, Gonçalves I, Nilsson J., High plasma levels of heparin-binding epidermal growth factor are associated with a more stable plaque phenotype and reduced incidence of coronary events. Arterioscler Thromb Vasc Biol 2015 35 222 228. doi: 10.1161/ATVBAHA.114.304369
14. Dong Z, Kumar R, Yang X, Fidler IJ., Macrophage-derived metalloelastase is responsible for the generation of angiostatin in Lewis lung carcinoma. Cell 1997 88 801 810
15. Chandler S, Cossins J, Lury J, Wells G., Macrophage metalloelastase degrades matrix and myelin proteins and processes a tumour necrosis factor-alpha fusion protein. Biochem Biophys Res Commun 1996 228 421 429. doi: 10.1006/bbrc.1996.1677
16. Traylor M, Mäkelä KM, Kilarski LL, METASTROKE, International Stroke Genetics Consortium, Wellcome Trust Case Consortium 2 (WTCCC2) A novel MMP12 locus is associated with large artery atherosclerotic stroke using a genome-wide age-at-onset informed approach. PLoS Genet 2014 10 e1004469. doi: 10.1371/journal.pgen.1004469
17. Halpert I, Sires UI, Roby JD, Potter-Perigo S, Wight TN, Shapiro SD, Welgus HG, Wickline SA, Parks WC., Matrilysin is expressed by lipid-laden macrophages at sites of potential rupture in atherosclerotic lesions and localizes to areas of versican deposition, a proteoglycan substrate for the enzyme. Proc Natl Acad Sci USA 1996 93 9748 9753
18. Morgan AR, Rerkasem K, Gallagher PJ, Zhang B, Morris GE, Calder PC, Grimble RF, Eriksson P, McPheat WL, Shearman CP, Ye S., Differences in matrix metalloproteinase-1 and matrix metalloproteinase-12 transcript levels among carotid atherosclerotic plaques with different histopathological characteristics. Stroke 2004 35 1310 1315. doi: 10.1161/01.STR.0000126822.01756.99
19. Scholtes VP, Johnson JL, Jenkins N, Sala-Newby GB, de Vries JP, de Borst GJ, de Kleijn DP, Moll FL, Pasterkamp G, Newby AC., Carotid atherosclerotic plaque matrix metalloproteinase-12-positive macrophage subpopulation predicts adverse outcome after endarterectomy. J Am Heart Assoc 2012 1 e001040. doi: 10.1161/JAHA.112.001040
20. Liang J, Liu E, Yu Y, Kitajima S, Koike T, Jin Y, Morimoto M, Hatakeyama K, Asada Y, Watanabe T, Sasaguri Y, Watanabe S, Fan J., Macrophage metalloelastase accelerates the progression of atherosclerosis in transgenic rabbits. Circulation 2006 113 1993 2001. doi: 10.1161/CIRCULATIONAHA.105.596031
21. Johnson JL, George SJ, Newby AC, Jackson CL., Divergent effects of matrix metalloproteinases 3, 7, 9, and 12 on atherosclerotic plaque stability in mouse brachiocephalic arteries. Proc Natl Acad Sci USA 2005 102 15575 15580. doi: 10.1073/pnas.0506201102
22. Yamada S, Wang KY, Tanimoto A, Fan J, Shimajiri S, Kitajima S, Morimoto M, Tsutsui M, Watanabe T, Yasumoto K, Sasaguri Y., Matrix metalloproteinase 12 accelerates the initiation of atherosclerosis and stimulates the progression of fatty streaks to fibrous plaques in transgenic rabbits. Am J Pathol 2008 172 1419 1429. doi: 10.2353/ajpath.2008.070604
23. Johnson JL, Devel L, Czarny B, George SJ, Jackson CL, Rogakos V, Beau F, Yiotakis A, Newby AC, Dive V., A selective matrix metalloproteinase-12 inhibitor retards atherosclerotic plaque development in apolipoprotein E-knockout mice. Arterioscler Thromb Vasc Biol 2011 31 528 535. doi: 10.1161/ATVBAHA.110.219147
24. Jguirim-Souissi I, Jelassi A, Addad F, Hassine M, Najah M, Ben Hamda K, Maatouk F, Ben Farhat M, Bouslema A, Rouis M, Slimane MN., Plasma metalloproteinase-12 and tissue inhibitor of metalloproteinase-1 levels and presence, severity, and outcome of coronary artery disease. Am J Cardiol 2007 100 23 27. doi: 10.1016/j.amjcard.2007.01.069
25. Nilsson L, Jonasson L, Nijm J, Hamsten A, Eriksson P., Increased plasma concentration of matrix metalloproteinase-7 in patients with coronary artery disease. Clin Chem 2006 52 1522 1527. doi: 10.1373/clinchem.2006.067439
26. Murphy G, Cockett MI, Ward RV, Docherty AJ., Matrix metalloproteinase degradation of elastin, type IV collagen and proteoglycan. A quantitative comparison of the activities of 95 kDa and 72 kDa gelatinases, stromelysins-1 and-2 and punctuated metalloproteinase (PUMP). Biochem J 1991 277 (Pt 1) 277 279
27. Williams H, Johnson JL, Jackson CL, White SJ, George SJ., MMP-7 mediates cleavage of N-cadherin and promotes smooth muscle cell apoptosis. Cardiovasc Res 2010 87 137 146. doi: 10.1093/cvr/cvq042
28. Galis ZS, Muszynski M, Sukhova GK, Simon-Morrissey E, Libby P., Enhanced expression of vascular matrix metalloproteinases induced in vitro by cytokines and in regions of human atherosclerotic lesions. Ann N Y Acad Sci 1995 748 501 507
29. Montero I, Orbe J, Varo N, Beloqui O, Monreal JI, Rodríguez JA, Díez J, Libby P, Páramo JA., C-reactive protein induces matrix metalloproteinase-1 and-10 in human endothelial cells: implications for clinical and subclinical atherosclerosis. J Am Coll Cardiol 2006 47 1369 1378. doi: 10.1016/j.jacc.2005.10.070
30. Lemaître V, O'Byrne TK, Borczuk AC, Okada Y, Tall AR, D'Armiento J., ApoE knockout mice expressing human matrix metalloproteinase-1 in macrophages have less advanced atherosclerosis. J Clin Invest 2001 107 1227 1234. doi: 10.1172/JCI9626
31. Catania JM, Chen G, Parrish AR., Role of matrix metalloproteinases in renal pathophysiologies. Am J Physiol Renal Physiol 2007 292 F905 F911. doi: 10.1152/ajprenal.00421.2006
32. Andrade VL, do Valle IB, Sandrim VC., Simvastatin therapy decreases MMP-9 levels in obese women. J Clin Pharmacol 2013 53 1072 1077. doi: 10.1002/jcph.146